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Abstract
Background Oral drug formulations have several advantages compared to intravenous formulation. Apart from patient con-
venience and favorable pharmacoeconomics, they offer the possibility of frequent drug administration at home. In this study, 
we present a new oral irinotecan formulation designed as an enteric coated immediate release tablet which in pre-clinical 
studies has shown good exposure with low variability.
Methods A phase I, dose escalating study to assess safety, tolerability, pharmacokinetics and efficacy of an oral irinotecan 
formulation and to establish the maximum tolerated dose (MTD). Each treatment cycle was once-daily irinotecan for 14 days 
followed by 1 week rest.
Results 25 patients were included across four cohorts; 3 patients were included in cohort 1 (20 mg/m2), 7 patients were 
included in cohort 2 (30 mg/m2), 3 patients were included in cohort 3 (25 mg/m2) and 12 patients were included in cohort 4 
(21 mg/m2). Median age was 67 years, 52% were performance status (PS) 0 while 48% were PS 1. Median number of prior 
therapies was 3 (range 1–6). MTD was established at 21 mg/m2. No responses were observed. Nine patients (36%) had stable 
disease (SD), lasting median 19 weeks (range 7–45 weeks). Among these five patients had previously received irinotecan. No 
grade 3/4 hematologic toxicities were reported. Totally six patients experienced grade 1/2 anemia, three patients had grade 
1/2 leucopenia and 1 patient had grade 1 thrombocytopenia. Most common non-hematological grade 1 and 2 adverse events 
were nausea, fatigue, diarrhea, vomiting and cholinergic syndrome. Grade 3 toxicities included diarrhea, fatigue, nausea 
and vomiting, no grade 4 events were reported. PK data showed consistent daily exposures during treatment at days 1 and 
14 and no drug accumulation. SN-38 interpatient variability was in the same range as after infusion.
Conclusions Oral irinotecan was generally well tolerated; side effects were manageable and similar in type to those observed 
with intravenous irinotecan. Hematological toxicities were few and only grade 1/2. In this heavily pre-treated patient popula-
tion, oral irinotecan demonstrated activity even among patients previously treated with irinotecan.
Keywords Phase I · Oral irinotecan · Dose finding
Introduction
Irinotecan has been used in the treatment of various solid 
tumors for the past 2 decades and constitutes a corner stone 
in the treatment of metastatic colorectal, pancreatic and gas-
tric cancers [1–7].
Originally introduced as an intravenous therapy, the 
search for an oral formulation has been ongoing almost since 
the drug was introduced [8]. Oral drug formulations are gen-
erally preferred by patients due to comfort and convenience, 
they often carry health economic benefits and, in the case of 
irinotecan, some studies indicate that oral irinotecan might 
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be more effectively converted to the active metabolite SN-38 
compared to intravenous administration [9, 10]. Further, oral 
administration allows for the concept of frequent dosing i.e., 
giving the chemotherapy at frequent time intervals in lower 
doses.
Irinotecan is a pro-drug which is enzymatically converted 
to the biologically active metabolite SN-38 [11]. Whereas 
irinotecan is water soluble, SN-38 is practically insoluble in 
water. Following metabolization in the liver SN-38 is con-
verted to the water-soluble but inactive metabolite SN-38G. 
SN-38 is 100–1000 times more potent than irinotecan but 
the fraction of irinotecan actually converted to active SN-38 
is small and exhibits a very large inter-patient variability. 
Due to severe side effects this problem is not readily solved 
by increasing the dose of irinotecan [12, 13]. During the 
past 20 years, several studies including various oral formula-
tions of irinotecan have been conducted [8, 9, 14–19]. Oral 
bioavailability for both irinotecan and SN-38 has differed 
substantially among patients in the various studies [14–18]. 
The most common dose limiting toxicities have been diar-
rhea as well as nausea and vomiting. Despite fair efficacy 
results, none of the previously tested oral irinotecan for-
mulations have gone into phase II trials mainly because of 
problems concerning poor solubility and a substantial inter-
patient variability in the oral bioavailability. In clinical trials, 
various oral formulations have been tested including solu-
tions of i.v. irinotecan mixed with grape juice, powder filled 
capsules and semisolid matrix capsules, respectively. These 
formulations were all based on the water-soluble irinotecan 
hydrochloride, trihydrate salt [8–10, 18, 20]. More recently, 
preclinical studies have focused on improving solubility 
and increasing the bioavailability. In one study, SN-38 was 
encapsulated in lipid nano capsules and showed high perme-
ability, however, only 8% of SN-38 was released after 3 days 
[21]. Another study investigated the conjugation of SN-38 to 
poly-amido amine dendrimers which resulted in increased 
trans-epithelial transport. Drug release was 10%, 20% and 
56%, respectively, in simulated gastric, intestinal and liver 
environments [22]. Finally, pH-sensitive polymeric micelles 
of SN38 have been developed to improve permeability [23].
In the current study another approach has been used. The 
oral formulation in the present study is based on irinote-
can in the free base form being solubilized in a hydropho-
bic lipid system. The system is formulated into an enteric 
coated tablet to avoid release in the stomach, as the stom-
ach pH may influence the bio-absorption of irinotecan. The 
tablet releases the irinotecan immediately in the duodenum 
thereby avoiding protracted release. This is to ensure that 
the dosed irinotecan is eliminated before the next dose to 
avoid drug accumulation and to ensure high bio-absorption 
with low variability. In a pre-clinical repeat dose toxicity 
study, the irinotecan tablet was administered once daily for 
14 days within a 3-week cycle and compared to irinotecan 
i.v. administration on day 1. The small daily doses of the 
irinotecan tablet resulted in less gastro-intestinal side effects 
compared to i.v. administration. Further, the white blood cell 
counts were less affected.
The aim of the present study was to evaluate a new oral 
tablet formulation of irinotecan in a clinical phase I study. 
The main purpose of the present study was to evaluate the 
safety and tolerability of the new oral formulation and to 
identify the maximal tolerated dose (MTD) in patients upon 
repeated oral dosing. Further, the pharmacokinetics includ-
ing the interpatient variability were evaluated.
The study was designed as a standard dose escalating 
study with a subsequent extension trial in which the oral for-
mulation was tested in combination with oral capecitabine. 
Only the first part of the study is described here.
Patients and methods
Study design
The study was a phase I, dose escalating, single center study 
to investigate the safety, tolerability and MTD. The investi-
gational drug was designed and supplied by Oncoral Pharma 
ApS Denmark as an enteric coated immediate release tablet. 
The study drug was administered as tablets of either 7.5 mg 
or 10 mg. The total dose administered in mg was calculated 
as the body surface area (BSA) × dose in mg/m2. The num-
ber of tablets dispensed of each strength was selected to fit 
the total dose best possible.
One treatment cycle was 21  days and consisted of 
once-daily oral irinotecan for 14 days followed by 1 week 
rest, mimicking the most common used regimes with 
capecitabine.
The study was designed as a standard “3 + 3” design with 
an estimated 15–24 patients needed to establish the MTD. 
After reaching the MTD, an additional 12 patients were 
included to obtain sufficient data on safety and pharmacoki-
netics at the MTD level.
The starting dose was 20 mg/m2 daily followed by fixed 
increments of 10 mg/m2 with the opportunity to increase by 
only 5 mg/m2 in case of safety concerns. Progression to the 
next dose level was allowed if no dose limiting toxicities 
(DLT) were found in three patients. In case of a DLT occur-
rence, an additional three patients were to be included in the 
dose level and progression was only allowed if ≤ 1 patient 
experienced a DLT. If DLTs were found in ≥ 2 patients 
the study design was to be modified following safety data 
review. A safety board was established, and meetings were 
held prior to every dose escalation and on demand.
During the DLT period, i.e., the first two cycles, clinical 
safety assessment was performed at screening, on days 2, 
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5, 9, 14, 15, 22 in cycle one and once weekly in cycle two. 
Laboratory safety assessment was performed at screening, 
on days 5, 15 and 19 in cycle one and on days 8, 15 and 19 
in cycle two.
DLT was defined as neutropenia or thrombocytopenia 
grade 4 or bleeding due to thrombocytopenia, any grade 
3–4 adverse events thought to be treatment related, grade ≥ 3 
diarrhea, vomiting or nausea despite optimal treatment, 
moderate to severe symptoms of early cholinergic syndrome 
or other adverse reactions leading to treatment delay for 
more than 2 weeks.
Pharmacokinetics of irinotecan, SN-38 and SN-38G were 
investigated on days 1 and 14 of the first cycle, 10 min pre-
dosing and at 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 3.5 h, 4 h, 5 h, 6 h, 
8 h, 12 h and 24 h post dosing.
There were no restrictions on food intake during treat-
ment except for days 1 and 14 of pharmacokinetic sampling 
where the patients were fasted from 10 p.m. in the evening 
and until 1 h post dosing.
Any impact of food was investigated at the dose level 
21 mg/m2 (MTD) for six subjects taking the dose in fasted 
state on day 1 and in fed state on day 14, respectively.
Tumor response was evaluated according to RECIST 1.1 
[24] with CT scans at day 36 (after 2 cycles of treatment) 
and hereafter every 6 weeks.
UGT1A1
SN-38 is primarily metabolized to the inactive SN-38 glu-
curonide by uridine diphosphate-glucuronyl transferase 1A1 
(UGT1A1). UGT1A1 is an enzyme responsible for catalyz-
ing the glucuronidation of various compounds, including 
steroid hormones, bilirubin, as well as xenobiotics, such 
as irinotecan. A polymorphic variation in the promoter of 
UGT1A1 leads to decreased expression of UGT1A1, result-
ing in reduced glucuronidation of SN-38, the active metab-
olite of irinotecan. Some studies have indicated that the 
risk of irinotecan toxicity is increased among persons with 
genetic variants associated with reduced UGT enzyme activ-
ity. Thus, patients with a (TA)7 repeat (UGT1A1*28) are at 
increased risk of developing grade 4 neutropenia or severe 
diarrhea [25]. The FDA-approved drug label for irinotecan 
states that when irinotecan is administered as a single agent, 
a reduction in the starting dose by at least one level of iri-
notecan hydrochloride injection should be considered for 
patients known to be homozygous for the UGT1A1*28 allele 
[26, 27]. As a consequence, we decided to study the poly-
morphisms of UGT1A1 in all patients entering the study.
A UGT1A1 Genotyping Kit (UGT-RT50, EntroGen) 
was used. This is a polymerase chain reaction (PCR)-based 
assay with allele-specific probes, which identify the most 
common irinotecan polymorphic variant. Briefly, genomic 
DNA was extracted from whole blood (n = 25) and used for 
the multiplexed amplification of the promoter region of the 
UGT1A1 gene with oligonucleotide primers that flanks the 
UGT1A1*1/*28 SNP. The variants were detected using fluo-
rescent dyes [FAM labeled probes detect UGT1A1*1 (wild 
type), VIC labeled probes detect UGT1A1*28 (mutant)]. 
Samples were classified as: homozygote (UGT1A1*1 
or UGT1A1*28) and heterozygote (UGT1A1*1 and 
UGT1A1*28). Amplification was performed on an Applied 
Biosystems 7500 instrument.
Study population
Patients with metastatic or unresectable solid tumors for 
whom no standard treatment options existed were eligible 
for inclusion. Patients were required to be in performance 
status 0–1 according to ECOG [28], have a life expectancy 
of ≥ 3 month and adequate organ and bone marrow func-
tion. Furthermore, patients with chronic enteropathy, bowel 
obstruction or sub-obstruction, prior history of malabsorp-
tion or symptomatic brain metastases were excluded.
Study objectives
The primary objectives were to determine the safety, toler-
ability and MTD of oral irinotecan. Secondary objectives 
included pharmacokinetics and tumor response.
Statistical analysis
No formal statistical analyses were performed on safety or 
efficacy data. Descriptive statistics were used for patient 
demographics, safety and efficacy data.
Pharmacokinetic analysis
Concentrations of irinotecan, SN-38 and SN-38G in stabi-
lized human plasma samples were measured using LC-MS/
MS with protein precipitation extraction. The corrected 
lower limit of quantification (LLOQ) for irinotecan and 
SN-38 in human plasma was 0.110 ng/mL and 0.550 ng/mL 
for SN-38G. Values below were reported as below limit of 
quantification (BLQ). The extent of conversion of irinotecan 
to SN-38 was calculated as the metabolic ratio being AUC 
SN-38/AUC Iri. The extent of glucuronidation of SN-38 to SN-
38G was calculated as the glucuronidation ratio being AUC 
SN-38G/AUC SN-38.
Pharmacokinetic non-compartmental analysis was per-
formed using WinNonlin v6.3 on irinotecan and its metab-
olites SN-38 and SN-38G. A value of 0 was used for all 
human plasma concentrations recorded as BLQ prior to tmax 
and concentrations recorded as BLQ after tmax were set to 
missing. Estimation of t½ was subject to a minimum of 3 
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data points on the fitted line of regression, a measured por-
tion of the line of regression equivalent to at least 1.5 times 
the half-life and a coefficient of determination (R2) of at 
least 0.80.
Ethics
The study was performed in accordance with the Declaration 
of Helsinki, ICH-Good Clinical Practice and approved by the 
Regional Ethics Committee (H-15000878) of Denmark. All 
included patients provided written, informed consent. The 
study was initiated by the principal investigator at Herlev 
and Gentofte Hospital, Department of Oncology and partly 
sponsored by grants from the Innovation Foundation and the 
Danish Cancer Society and registered at EudraCT (2014-
005584-32) and at ClinicalTrials.Gov (NCT03295084).
Results
Patient characteristics
From July 2015 to September 2017, 25 patients were 
included across 4 treatment cohorts; 3 patients were included 
in cohort 1 (20 mg/m2), 7 patients were included in cohort 
2 (30 mg/m2), 3 patients were included in cohort 3 (25 mg/
m2) and 12 patients were included in cohort 4 (21 mg/m2). 
According to the protocol, one patient in cohort 2 was 
replaced as this patient was withdrawn due to cancer-related 
complaints after only 4 days of dosing with irinotecan.
Included patients were median 67  years old (range 
51–82), 52% were performance status (PS) 0 while 48% 
were PS 1. Among the included patients, six had a diag-
nosis of cholangiocarcinoma, five had a diagnosis of colon 
cancer, four had pancreas and prostate cancer, respectively, 
and one each had cervical cancer, NSCLC, ovarian cancer, 
rectal cancer, SCLC and mesothelioma. Median number of 
prior therapies was 3 ranging from 1 to 6.
Patients’ characteristics are summarized in Table 1.
Dose escalation and dose limiting toxicities
In cohort 1, no DLTs were observed. At progression to next 
dose level (30 mg/m2), one patient experienced diarrhea 
grade 3 and thus three more patients were included. As one 
more patient experienced grade 3 diarrhea, the MTD was 
exceeded and the dose level was lowered to 25 mg/m2. Three 
patients were included; one grade 3 diarrhea accompanied 
with dehydration grade 3 was reported as well as elevated 
alkaline phosphatase grade 3.
Following a safety board meeting, the dose was lowered 
to 21 mg/m2 and this dose was accepted as MTD.
The median treatment duration in cohort 1–4 was 70 days 
(range 35–97), 9 days (range 4–35), 11 days (range 5–119) 
and 35.5 days (range 2–228), respectively. Total doses of 
irinotecan were 1640 mg, 450 mg, 440 mg and 1100 mg, 
respectively, in cohorts 1, 2, 3 and 4. The shorter treatment 
periods in cohorts 2 and 3 are reflected in the lower total 
doses. Among the 15 patients treated in either cohort 1 or 
4 at the MTD, the median dose of irinotecan was 1120 mg 
(range 71–8190 mg).
Pharmacokinetics
The pharmacokinetic parameters of Irinotecan, SN-38 and 
SN-38G were determined in totally 25 patients on day 1 
and day 14 of the first cycle. As the three patients in cohort 
1 (20 mg/m2) were dosed 20.9 mg/m2 and within the range 
Table 1  Patient demographics and disease characteristics (25 
patients)
Characteristics Number of 
patients (%)
Median age, years (range) 67 (51–82)
Gender
 Male 14 (56)
 Female 11 (44)
ECOG performance status
 0 13 (52)
 1 12 (48)
Primary cancer
 Cholangiocarcinoma 6 (24)
 Colon 5 (20)
 Pancreas 4 (16)
 Prostate 4 (16)
 Cervix 1 (4)
 Mesothelioma 1 (4)
 NSCLC 1 (4)
 Ovarian 1 (4)
 Rectum 1 (4)
 SCLC 1 (4)
Extent of disease
 Locally advanced 5 (20)
 Metastatic 20 (80)
Median number of prior regimen for advanced disease 
(range)
3 (1–6)
Prior treatment with irinotecan
 Yes 15 (60)
 No 10 (40)
UGT1A1
 UGT1A1*1/1 homozygote 13 (52)
 UGT1A1*1/28 heterozygote 10 (40)
 UGT1A1*28/28 homozygote 2 (8)
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of dosing for cohort 4 (21 mg/m2) the patients of cohorts 1 
and 4 were merged into a common cohort 4, i.e., dose level 
21 mg/m2 for the pharmacokinetic evaluation.
The pharmacokinetic data for irinotecan, SN-38 and SN-
38G on both days are provided in Table 2 and plasma pro-
files of irinotecan, SN-38 and SN-38G on day 1 are provided 
in Fig. 1.
At the MTD level (21 mg/m2 dose level), mean Cmax lev-
els of 19.2 ng/mL and 15.2 ng/mL and mean AUC 0–24 levels 
of 135 h ng/mL and 133 h ng/mL, respectively, were found 
on day 1 and day 14 for irinotecan. Median time to observe 
maximum concentration (tmax) for irinotecan was 3 h on 
both days. For SN-38 mean Cmax levels of 2.67 ng/mL and 
2.19 ng/mL and mean AUC 0–24 levels of 22.5 and 21.6 ng/
mL were found with a median tmax of 4 h on both day 1 and 
day 14. The metabolic ratios of SN-38/irinotecan at MTD 
were consistent after 14 days of repeat dosing with AUC 0–24 
ratios of 0.175 (17.5%) and 0.163 (16.3%), and Cmax ratios 
of 0.142 and 0.145 on day 1 and day 14, respectively. The 
metabolic AUC 0–24 ratios of SN-38G/SN-38 were 6.38 and 
6.78 and Cmax ratios were 5.45 and 5.91 on day 1 and day 
14, respectively.
The geometric means day 14 over day 1 exposure ratio 
of irinotecan for Cmax and AUC 0–24 were 0.85 and 1.08, 
respectively, and 0.87 and 1.00 for SN-38. The geometric 
mean trough concentration C24 prior to dosing at day 14 
was 1.95 ng/mL for irinotecan and 0.631 ng/mL for SN-38. 
Both the geometric mean day 14 over day 1 exposure ratio 
and the C24 level indicate no drug accumulation of relevance 
for irinotecan and SN-38.
The inter-patient coefficient of variation (CV%) in SN-38 
exposure (based on AUC 0–t) was 63.3% on day 1 and 42.6% 
day 14 for SN-38.
The geometric mean AUC 0–t obtained was 159 h ng/mL 
and 124 h ng/mL in fasted and fed state, respectively. The 
fed/fasted ratio of the geometric mean AUC 0–24 for the six 
patients taking the irinotecan tablet in fasted state at MTD 
on day 1 and in fed state on day 14 was 0.776 for irinotecan 
and 0.791 for SN-38 with a range from 0.145 to 2.17 for 
irinotecan and 0.218 to 1.58 for SN-38 as some patients 
experienced somewhat higher AUC 0–24 on day 1 in fasted 
state and others on day 14 after a meal.
Increasing the doses to 25  mg/m2 and to 30  mg/m2 
resulted in increases in both geometric mean Cmax and AUC 
0–t of irinotecan. For SN-38 the exposure increased with 
increasing dose in a manner that was greater than dose pro-
portional between the 21 and 25 mg/m2 dose levels, and 
proportional between the 25 and 30 mg/m2 doses. In gen-
eral, there was not enough data at day 14 for the dose levels 
25 mg/m2 and 30 mg/m2 to draw any firm pharmacokinetic 
conclusions.
Table 2  Pharmacokinetic parameters of irinotecan, SN-38 and SN-38G
Data as geometric mean (SD) except for tmax as median (range). Individual PK parameters are listed if n < 3
NC not calculated
a n = 14; bn = 12; cn = 8; dn = 7; en = 3; fn = 2; gn = 4; hn = 5
Dose (no. patients) Parameters Irinotecan SN-38 SN-38G
Day 1 Day  14a Day 1 Day  14a Day 1 Day  14a
21 mg/m2/day (n = 15) Cmax (ng/mL) 19.2 (16.5) 15.2 (9.54) 2.67 (2.41) 2.19 (1.92) 13.8 (22.2) 13.0 (8.85)
tmax (h) 3.0 (1.5–6.0) 3.0 (1.5–6.0) 4.0 (1.5–5.0) 4.0 (2.0–8.0) 5.0 (3.5–6.0) 5.5 (2.5–12)
AUC 0–24 (ng h/mL) 135 (114) 133 (66.9) 22.5 (14.3) 21.6 (9.22) 149 (210) 146 (117)
AUC 0–∞ (ng h/mL) 142 (130)a 150 (75.0)c 31.3 (17.9) 19.7 (4.86)e 154 (263) 172 (63.0)g
t½ (h) 6.78 (0.96)a 7.63 (0.99)c 7.88 (2.16)d 11.0 (1.10)e 7.63 (1.30)b 8.68 (0.62)g
Cmax (Day14/Day1) – 0.85 (0.82) – 0.87 (1.48) – 0.94 (0.73)
AUC 0–24 (Day14/Day1) – 1.08 (0.84) 1.00 (0.65) 1.06 (0.70)
25 mg/m2/day (n = 3) Cmax (ng/mL) 46.7 (12.1) 34.6 (n = 1) 7.91 (6.39) 2.81 (n = 1) 27.9 (16.6) 11.6 (n = 1)
tmax (h) 2.0 (2–2.5) 2.0 (n = 1) 2.5 (2.0–4.0) 3.5 (n = 1) 3.5 (2.5–5.0) 3.5 (n = 1)
AUC 0–24 (ng h/mL) 317 (167) 237 (n = 1) 51.7 (46.8) 22.9 (n = 1) 261 (279) 100 (n = 1)
AUC 0−∞ (ng h/mL) 264 (n = 2) 274 (n = 1) 51.8 (n = 1) NC 279 (n = 1) NC
t½ (h) 6.59 (n = 2) 8.88 (n = 1) 7.13 (n = 1) NC 5.56 (n = 1) NC
30 mg/m2/day (n = 7) Cmax (ng/mL) 70 (35.9) 70.5 (n = 2) 8.99 (6.23) 6.04 (n = 2) 38.8 (25.2) 24.3 (n = 2)
tmax (h) 2.5 (1.5–3.0) 2.0 (n = 2) 2.5 (1.5–6.0) 1.8 (1.5–2.0)f 3.0 (2.5–6.0) 3.5 (n = 2)
AUC 0–24 (ng h/mL) 445 (191) 442 (n = 2) 58.5 (35.5) 39.0 (6.51)f 378 (329) 242 (n = 2)
AUC 0−∞ (ng h/mL) 497 (240) 493 (n = 2) 61.9 (n = 1) NC 439 (236)h 285 (n = 2)
t½ (h) 7.46 (1.29) 7.31 (n = 2) 8.92 (n = 1) NC 8.56 (0.87)h 8.37 (n = 2)
174 Cancer Chemotherapy and Pharmacology (2019) 83:169–178
1 3
UGT1A1
In total, 25 blood samples from patients included were ana-
lyzed. We did perform all analyses in duplicate to ensure 
consistent results. The detected variants found were clas-
sified as homozygote UGT1A1*1; 13 (52%), homozygote 
UGT1A1*28; 2 (8%) and heterozygote 10 (40%). Of two 
patients homozygote for UGT1A1*28, one patient expe-
rienced a grade 3 diarrhea and withdrew the study due 
to toxicity. The following CT scan showed stable disease 
(SD). The other patient terminated the study early due to 
cancer-related complaints and only received oral irinotecan 
for 4 days. Among the remaining patients with grade 3 diar-
rhea one was heterozygote for UGT1A1*28 and three were 
homozygote for UGT1A1*1. Additionally, patients with 
SD were found among both UGT1A1*1 homozygote and 
UGT1A1*28 heterozygote.
Safety
Only grade 1 and 2 hematologic toxicities were reported. 
Totally six patients across all cohorts experienced grade 1/2 
anemia, three patients had grade 1/2 leucopenia and only one 
patient had grade 1 thrombocytopenia (Table 3).
Most common non-hematological grade 1 and 2 adverse 
events were nausea, fatigue, diarrhea, vomiting and cho-
linergic syndrome (Table 4). Across cohorts 1–3 DLTs 
were observed in four patients and included diarrhea (three 
patients) and increased alkaline phosphatase (one patient). 
In cohort 4, totally four patients experienced grade 3 AEs 
probably or possible related, these included diarrhea, nau-
sea, vomiting, spleen infarction, cataract, increased blood 
bilirubin, fatigue and deterioration of general condition 
(Table 4). Totally 13 patients (52%) discontinued the study 
due to unacceptable side effects. In cohort 4, five patients 
(42%) discontinued due to toxicities.
0
5
10
15
20
25
30
35
40
0 4 8 12 16 20 24
Pl
as
m
a 
le
ve
l (
ng
/m
l)
Hours
Irinotecan, day 1
21 mg/m2
Fig. 1  Pharmacokinetic plasma profiles of irinotecan, SN-38 and SN-
38G on day 1 (mean values + SEM, n = 15)
Table 3  Treatment-emergent abnormal hematological laboratory values
Grade 3 or 4 decreased values were not observed
ANC absolute neutrophil count, WBC white blood cell count
20 mg/m2 (n = 3) 30 mg/m2 (n = 7) 25 mg/m2 (n = 3) 21 mg/m2 (n = 12) Total (n = 25)
Grade 1
n (%)
Grade 2
n (%)
Grade 1
n (%)
Grade 2
n (%)
Grade 1
n (%)
Grade 2
n (%)
Grade 1
n (%)
Grade 2
n (%)
Grade 1
n (%)
Grade 2
n (%)
Hemoglobin 1 (33.3) 1 (33.3) 1 (14.3) 2 (28.6) 0 0 1 (8.3) 0 3 (12) 3 (12)
WBC 1 (33.3) 1 (33.3) 0 0 0 0 0 1 (8.3) 1 (4) 2 (8)
ANC 0 0 0 0 0 0 0 0 0 0
Platelets 0 0 0 0 0 0 1 (8.3) 0 1 (4) 0
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Efficacy
No complete or partial responses were observed. Nine 
patients (36%) had SD at first response evaluation, lasting 
median 19 weeks (range 7–45 weeks). Among patients with 
SD three had a diagnosis of colon cancer, three had cholan-
giocarcinoma and one each had SCLC, mesothelioma and 
ovarian cancer. Among patients with SD, five had previously 
received intravenous irinotecan.
Totally eight patients were non-evaluable as they discon-
tinued the study due to toxicities and no CT scan was per-
formed at the end of treatment.
Discussion
Oral drug formulations possess several advantages compared 
to intravenous formulations. Apart from patient convenience 
and favorable pharmacoeconomics, they offer the possibility 
of out-hospital drug administration at frequent intervals at 
lower doses. As no oral irinotecan formulations have been 
approved, clinical data on frequent dosing with irinotecan 
are sparse. However, data from the few published studies 
seem to indicate that frequent dosing is well tolerated and 
possibly more efficacious than more protracted administra-
tion schedules [29–31].
Several attempts have been made to develop a safe and 
efficient oral administration of irinotecan using a dosing 
regimen of either 5 or 14 days of treatment within 3 weeks 
treatment cycles [8–10, 18, 20].
These studies indicate that it is most likely the cumulative 
dose within a treatment cycle that defines DLT and thereby 
the MTD. Treatment once daily for 5 days within a 3-week 
cycle resulted in MTDs in the range 50–80 mg/m2 of iri-
notecan, hydrochloride, and trihydrate, whereas treatment 
once daily for 14 days resulted in MTDs in the range of 
30–40 mg/m2 of irinotecan, hydrochloride, and trihydrate. In 
the present study, a MTD of 21 mg/m2 irinotecan (free base) 
corresponding to 24 mg/m2 of irinotecan, hydrochloride, tri-
hydrate was administered daily providing a cumulative dose 
of approximately 340 mg/m2 within each 3-week treatment 
cycle. This cumulative dose corresponds well with the com-
monly used dose 340 mg/m2 provided as i.v. administration 
every 3 weeks [27].
The pharmacokinetic data of the present study showed 
that irinotecan was rapidly and well absorbed and con-
verted to its active metabolite SN-38 upon oral adminis-
tration. Oral irinotecan was more effectively converted to 
SN-38 compared to intravenous administration as conver-
sion was approximately six- to sevenfold higher following 
oral administration. The metabolic ratio of SN38/irinotecan 
was in the range of 16.3–16.6% compared to 2.3% following 
i.v. administration. The gastro-intestinal tract contains high 
levels of the carboxylesterase enzyme most likely respon-
sible for the additional conversion to SN-38. Plasma peaks 
of irinotecan and SN-38 occurred after approximately 3 h. 
The absorbed irinotecan was eliminated within 24 h with no 
evidence of accumulation upon repeated dosing. Thus, the 
current treatment regimen appeared to be safe in relation to 
drug accumulation and provided consistent daily exposures 
during treatment from day 1 to day 14 within each cycle.
The cumulative exposure of SN-38 within a 3-week cycle 
was in the same range as that obtained following a single 
i.v. administration of 340 mg/m2 (approximately 315 ng/mL 
versus 474 ng/mL) [27].
The inter-patient coefficient of variation in SN-38 expo-
sure (AUC 0–24) after i.v. dosing has been reported to be 
approximately 47–51% and is most likely linked to the com-
plex pharmacokinetics of the drug. The CV% for the active 
metabolite SN-38 after oral administration of the irinotecan 
tablet was 43–63% which is comparable to that of i.v. treat-
ment [26].
The impact of food on oral irinotecan was investigated in 
six patients. In accordance with previously published data, 
no significant effect on absorption of irinotecan was found 
following food intake [19].
Grades 3 and 4 late diarrhea appear in 16–22% of patients 
after i.v. administration of irinotecan [32]. SN-38G is con-
sidered responsible for the delayed diarrhea through biliary 
excretion and increased SN-38 exposure in the gut. Totally 
five patients experienced grade 3 diarrhea after oral dos-
ing in the present study, respectively, three patients after 
exposure to 30 mg/m2, one patient after exposure to 25 mg/
m2 and one patient at MTD after oral dosing in the present 
study. However, no correlation was found between grade 3 
Table 4  Treatment-related adverse events at MTD level 21 mg/m2 (12 
patients)
Grade 4 adverse events were not observed
a In addition the following grade 3 adverse events were observed; 
increased blood bilirubin, cataract (worsening), infarction of spleen 
and deterioration of general condition
Grade 1/2
n (%)
Grade  3a
n (%)
All grade
n (%)
Fatigue 4 (33.3) 1 (8.3) 5 (41.7)
Weight loss 4 (33.3) 0 4 (33.3)
Constipation 0 0 0
Diarrhea 6 (50.0) 1 (8.3) 7 (58.3)
Nausea 7 (58.3) 1 (8.3) 8 (66.7)
Vomiting 6 (50.0) 1 (8.3) 7 (58.3)
Cholinergic syndrome 4 (33.3) 0 4 (33.3)
Mucositis 4 (33.3) 0 4 (33.3)
Dyspnea 1 (8.3) 0 1 (8.3)
Fever 1 (8.3) 0 1 (8.3)
Febrile neutropenia 0 0 0
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diarrhea and the levels of SN-38G or the SN-38G/SN-38 
ratios found in the patients.
UGT1A1 plays a role in the glucuronidation of SN-38 
and it has been speculated whether a screening for 
UGT1A1*28 polymorphism could identify patients with 
lower SN-38 glucuronidation rates and a greater suscep-
tibility to irinotecan induced diarrhea [33]. Although a 
limited number of patients were included in this study 
no correlation between UGT1A1 variants and toxicity or 
response was identified. This agrees with findings from 
another study of oral irinotecan where no correlation 
was found between irinotecan associated toxicity and the 
UGT1A1*28 genotype [19].
Non-hematological side effects such as late diarrhea, nau-
sea and vomiting are common following i.v. administration. 
Grades 3 and 4 diarrhea were reported in 30.6% of patients, 
grades 3 and 4 nausea in 16.8% of patients and grades 3 and 
4 vomiting in 12.5% of patients after i.v. administration [19]. 
The non-hematological side effects following administration 
of the irinotecan tablet were comparable to those observed 
following i.v. formulations but less severe [4, 6, 7]. In our 
study, most non-hematological side effects were of grade 1 
or 2. Only one subject (8.3%) experienced grade 3 diarrhea, 
vomiting or nausea, respectively at the MTD level.
Myelosuppression is a common toxicity following i.v. 
administration of irinotecan and possesses a serious threat 
to patients on chemotherapy. Thus, while hematologic side 
effects grades 3 and 4 are reported following i.v. adminis-
tration of irinotecan in 10–31.4% of patients participating 
in clinical trials [27, 34–37], no grade 3 or 4 hematologic 
toxicities were reported in the present study, indicating that 
the oral administration may have a favorable hematologic 
profile compared to intravenous administration. This is most 
likely due to the administration of small daily oral doses in 
contrast to a large dose administered intravenously weekly 
or every third week [4, 6, 7].
No objective responses were seen in this heavily pre-
treated cohort, however, nine (36%) patients did obtain a 
clinical benefit with SD lasting median 19 weeks. Among 
these, five patients (56%) had previously been treated with 
intravenous irinotecan.
In conclusion, we found the oral formulation to be safe 
and efficacious with less hematologic side effects. Our tablet 
formulation is currently investigated in combination with 
capecitabine.
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